The study will evaluate the safety, tolerability, and ability of 18F-OP-801 to cross the blood-brain barrier and selectively target neuroinflammation in individuals with amyotrophic lateral sclerosis,...
REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (œAshvattha), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue...
REDWOOD CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (œAshvattha), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue...
REDWOOD CITY, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue...
Open-label study will evaluate the safety and efficacy of chronic D-4517.2 dosing in patients with wet age-related macular degeneration (wet AMD) or diabetic macular edema (DME)Favorable safety and...
REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (œAshvattha), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue...
Data demonstrated that ASH41020, a novel CSFR1 tyrosine kinase inhibitor ˜dendranib™, directs macrophage polarization toward the anti-inflammatory M2 phenotypeASH41020 treatment lessened disease...
Data will showcase anti-inflammatory and immunomodulatory effects of ASH41020, a novel CSFR1 tyrosine kinase inhibitor ˜dendranib™, in a mouse model of multiple sclerosis REDWOOD CITY, Calif.,...
REDWOOD CITY, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (œAshvattha), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers...
Ashvattha Therapeutics Presents Preclinical Data on anti-VEGF Nanomedicine D-4517.2 at the 2023 ARVO Annual Meeting